Difficult-to-Treat (DTT) and Severe Asthma — Comprehensive MD Examination Answer (15 Marks)

1. Definition and Terminology

The key distinction: DTT asthma may be controllable once modifiable factors are addressed; severe asthma is uncontrolled despite addressing those factors.

2. Epidemiology

• Comprises ~5–10% of all asthma patients
• Responsible for ~50% of asthma healthcare costs

• 50% have evidence of persistent eosinophilic inflammation (peripheral eosinophilia and/or elevated sputum eosinophils)

• Those with recurrent exacerbations have significantly higher likelihood of responding to Type 2 (T2) targeted biologics

3. Step-wise Evaluation Before Labelling as "Difficult-to-Treat"

A. Confirm Diagnosis

• Bronchiectasis
• COPD (or COPD-asthma overlap)
• Vocal cord dysfunction (VCD) / inducible laryngeal obstruction
• Cardiac conditions (heart failure)
• Vasculitis (e.g., EGPA / Churg-Strauss)
• Bronchomalacia
• Lung masses / endobronchial tumors

B. Modifiable Factors (Table — Factors Contributing to Worsening Control)

4. Pathophysiology and Phenotyping

Type 2 (T2)-High Inflammation (≥50–60% of severe asthma)

• Driven by IL-4, IL-5, IL-13, and IgE
• Biomarkers: elevated blood/sputum eosinophils, raised FeNO (>25 ppb), elevated serum IgE, elevated periostin
• Subtypes:
  • Allergic (atopic) — elevated IgE, allergen sensitization, responds to anti-IgE
  • Eosinophilic — peripheral eosinophilia ≥150–300 cells/μL, responds to anti-IL-5/IL-5R
  • Aspirin-exacerbated respiratory disease (AERD) — nasal polyps + aspirin sensitivity + eosinophilia

Type 2 (T2)-Low Inflammation

• Includes neutrophilic and paucigranulocytic phenotypes
• Pathways not fully defined; possible role of neutrophilic inflammation, mast cells, IL-6, IL-33
• May have aberrations in pro-resolving pathways
• Treatment remains challenging; macrolides may benefit a subset
• Tezepelumab (anti-TSLP) shows effectiveness even in T2-low patients

Obesity-related Asthma

• Obesity reduces corticosteroid efficacy
• Mechanically compresses airways; multiple non-T2 mechanisms
• Weight loss is therapeutic

Genetic Factors

• GWAS have identified >73 asthma susceptibility loci including RAD50/IL13, HLA-DQB1, IL33, ORMDL3, GSDMB, TSLP, GATA3
• Rare patients have biochemical abnormalities in steroid response pathways

5. Assessment / Workup

Clinical

• Full symptom history, frequency of exacerbations, hospitalizations, OCS use
• Occupational history (occupational asthma accounts for ~25% of adult-onset asthma)
• Validated tools: ACQ (Asthma Control Questionnaire), ACT

Pulmonary Function Tests

• Spirometry: pre- and post-bronchodilator FEV₁, FEV₁/FVC
• Bronchoprovocation testing if spirometry normal
• Serial PEF monitoring
• Normalization of arterial PCO₂ without clinical improvement = impending respiratory failure

Biomarkers for Phenotyping

Additional Investigations

• Chest X-ray / HRCT (exclude bronchiectasis, structural disease)
• Nasal endoscopy (polyps, sinusitis)
• ENT evaluation
• Screen for GERD (pH-impedance study)
• Sleep study (OSA)
• Psychiatric assessment

6. Management

Step-up Pharmacotherapy (GINA Steps 4–5)

• Medium-to-high dose ICS + LABA (combination inhaler)
• Add-on: LAMA (tiotropium) — shown to reduce exacerbations and improve FEV₁ as add-on to ICS/LABA
• Add-on: Leukotriene receptor antagonist (LTRA/LTM)

• Add LAMA (tiotropium)
• Consider biologic therapy
• Low-dose oral corticosteroids (OCS) — last resort due to significant systemic side effects

• Effective as add-on, especially in aspirin-exacerbated disease, exercise-induced bronchoconstriction, and concurrent allergic rhinitis
• Montelukast, zafirlukast, zileuton

7. Biologic (Targeted) Therapies

Mechanism of Action Summary

• Anti-IgE (omalizumab): Binds free circulating IgE → prevents IgE binding to FcεRI on mast cells and basophils → blocks allergic cascade
• Anti-IL-5 (mepolizumab, reslizumab): Block IL-5 ligand → reduce eosinophil production, survival, and tissue recruitment
• Anti-IL-5R (benralizumab): Binds IL-5 receptor α → direct apoptosis of eosinophils via ADCC
• Anti-IL-4Rα (dupilumab): Blocks shared IL-4Rα subunit → inhibits both IL-4 and IL-13 signalling
• Anti-TSLP (tezepelumab): Blocks the epithelial alarm signal TSLP → upstream suppression of both T2 and non-T2 inflammation

8. Non-Pharmacologic Interventions

Bronchial Thermoplasty

• Indicated for adults ≥18 years with severe persistent asthma not controlled on ICS/LABA
• Delivers controlled radiofrequency energy to airway walls via flexible bronchoscope → reduces airway smooth muscle mass → decreases bronchoconstriction
• Performed in three sessions (right lower lobe, left lower lobe, both upper lobes) 3 weeks apart
• Reduces severe exacerbations and emergency department visits

Allergen Immunotherapy

• Subcutaneous immunotherapy (SCIT) in allergic asthmatics with identified perennial allergen sensitization
• Reduces allergen sensitivity and inflammatory response over time

Weight Loss / Bariatric Surgery

• Obesity-related asthma: significant improvement in asthma control with weight reduction

Macrolide Antibiotics

• Low-dose azithromycin (3x/week) — evidence of benefit in some non-eosinophilic (neutrophilic) severe asthma patients; reduces exacerbation frequency
• Mechanism: immunomodulatory, not just antibacterial

9. Management of Acute Severe Asthma Exacerbations in DTT Patients

• SABA (albuterol/salbutamol) 2.5–5 mg via nebulizer q20 min × 3 doses, or continuous nebulization 10–15 mg/hr with telemetry monitoring for severe cases
• Ipratropium 0.5 mg q20 min — add for severe exacerbations; reduces hospitalisation rate (benefit not sustained after admission)
• Systemic corticosteroids: IV methylprednisolone 1.5–2 mg/kg (or equivalent oral) — first-line; early administration reduces need for hospitalization
• IV magnesium sulphate: 2 g bolus (40 mg/kg in children, max 2 g) — smooth muscle relaxant; reduces hospital admission rates
• Supplemental O₂ to maintain SpO₂ >90%
• High-risk features for near-fatal attack: recent prior hospitalisation/near-fatal episode, SABA overuse, ICS underuse, recent OCS use, poor action plan compliance, psychiatric comorbidity
• Rising PaCO₂ with no clinical improvement = impending respiratory failure → prepare for intubation
• Low-level non-invasive ventilation (NIV without PEEP) can be considered in alert, cooperative patients
• Heliox (helium-oxygen mixture) as adjunct in severe cases unresponsive to initial treatment
• Mechanical ventilation if deteriorating: use permissive hypercapnia, low tidal volumes, long expiratory time (avoid dynamic hyperinflation)

10. Monitoring and Follow-Up

• Review biologic response at 6–12 months
• Criteria for biologic response: reduced OCS use, fewer exacerbations, reduced emergency visits/hospitalisations, improved QoL scores and lung function
• Attempt step-down once control achieved for a sustained period
• If controlled on ICS alone: reduce dose or frequency
• Avoid LABA monotherapy during step-down (associated with worse outcomes)

11. Special Situations

• Asthma + chronic rhinosinusitis with nasal polyps + NSAID/aspirin hypersensitivity
• Treat with LTRAs + biological (dupilumab highly effective for CRSwNP/asthma); aspirin desensitization in selected cases

• Smoking blunts ICS response; earlier LAMA initiation appropriate
• Dupilumab approved for COPD with eosinophilic inflammation

• Sensitization to Aspergillus (or other molds) in severe asthma
• Antifungal therapy (itraconazole) may reduce exacerbations
• Allergic bronchopulmonary aspergillosis (ABPA) is the extreme form

12. Summary Algorithm

Poorly controlled asthma despite medium-high dose ICS/LABA
        ↓
Confirm diagnosis (exclude mimics)
        ↓
Address modifiable factors: adherence, inhaler technique, triggers, comorbidities
        ↓
Still uncontrolled? → DIFFICULT-TO-TREAT ASTHMA
        ↓
Phenotype with biomarkers (IgE, AEC, FeNO, allergen testing)
        ↓
   ┌─────────────────┬──────────────────┬──────────────────┐
   ↓                 ↓                  ↓                  ↓
Allergic T2      Eosinophilic T2     T2-High (mixed)    T2-Low
(IgE ↑, allergen  (AEC ↑, FeNO ↑)   (AEC + FeNO ↑)    (neutrophilic/
 sensitized)                                              paucigranulocytic)
   ↓                 ↓                  ↓                  ↓
Omalizumab     Mepolizumab/         Dupilumab          Tezepelumab /
               Benralizumab/        Tezepelumab        Macrolides / 
               Reslizumab                               Low-dose OCS (last resort)

Key Points for Exam

1. DTT ≠ Severe asthma — DTT may improve with modifiable factor correction; severe asthma is refractory despite all corrections
2. 5–10% of asthma is severe; accounts for ~50% of costs
3. Systematic evaluation of 8 modifiable factors before escalating therapy
4. >50% have T2-high eosinophilic phenotype — driven by IL-4, IL-5, IL-13
5. Biologic selection is biomarker-driven: IgE (omalizumab), AEC (anti-IL-5 agents), FeNO + AEC (dupilumab), all-comer (tezepelumab)
6. Tezepelumab (anti-TSLP) has the broadest indication — works in T2-low disease
7. Bronchial thermoplasty = non-pharmacologic procedural option for severe persistent asthma
8. Macrolides — benefit neutrophilic/T2-low severe asthma
9. Acute exacerbation: SABA + ipratropium + systemic corticosteroids + IV magnesium sulphate ± heliox ± NIV
10. Rising PaCO₂ without improvement = impending respiratory failure